These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11558698)

  • 21. Potential stifling effects of pharmaco-economics and regulatory policies.
    Data JL
    Am J Cardiol; 1998 Apr; 81(8A):34F-35F. PubMed ID: 9604904
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?
    Andersson F
    Int J Technol Assess Health Care; 1995; 11(4):750-61. PubMed ID: 8567207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indication-specific Drug Pricing - Simple in Theory, Complex in Reality.
    Kwon S
    Manag Care; 2018 May; 27(5):23-25. PubMed ID: 29763404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Canadians are killing us.
    Struble RA
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58-9. PubMed ID: 12592981
    [No Abstract]   [Full Text] [Related]  

  • 26. The pharmaceutical industry--to whom is it accountable?
    Summers WK; Driscoll J; Orient JM
    N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183883
    [No Abstract]   [Full Text] [Related]  

  • 27. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L; McGowan B; Bennett K; Barry M
    Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. US seeking more transparency from pharma.
    Collier R
    CMAJ; 2016 Apr; 188(7):E115. PubMed ID: 26976964
    [No Abstract]   [Full Text] [Related]  

  • 30. The cost of prescription drugs: rising concerns over equity, fairness and access to essential care.
    Work DR; Domino ME
    N C Med J; 2003; 64(6):270-4. PubMed ID: 14983614
    [No Abstract]   [Full Text] [Related]  

  • 31. The scandal of generic drug pricing: drug regulation policies need review.
    Meeran K; Choudhury SM; Wass J
    BMJ; 2017 Feb; 356():j947. PubMed ID: 28232321
    [No Abstract]   [Full Text] [Related]  

  • 32. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Problematic Jumps in Drug Prices and What You Can Do.
    Shaughnessy AF
    Am Fam Physician; 2017 Jul; 96(1):16-18. PubMed ID: 28671371
    [No Abstract]   [Full Text] [Related]  

  • 34. Regulation of pharmaceutical prices: a managed care perspective.
    Navarro RP
    Pharmacoeconomics; 1993 Mar; 3(3):179-82. PubMed ID: 10146942
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacoeconomics: the new dismal science.
    Luchins DJ
    Adm Policy Ment Health; 2004 May; 31(5):425-7. PubMed ID: 15379388
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
    Darba J
    Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacoeconomics comes of age?
    Walley T; Breckenridge A
    Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
    Golec J; Vernon JA
    Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmaceutical industry--to whom is it accountable?
    Rightor N
    N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183882
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.